Rock Springs Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-222,011
| Closed | -$1.67M | – | 94 |
|
|
2025
Q1 | $1.67M | Sell |
222,011
-2,455,985
| -92% | -$18.4M | 0.1% | 81 |
|
|
2024
Q4 | $20.1M | Sell |
2,677,996
-944,362
| -26% | -$7.1M | 0.77% | 45 |
|
|
2024
Q3 | $27.5M | Buy |
3,622,358
+3,100
| +0.1% | +$23.6K | 0.9% | 42 |
|
|
2024
Q2 | $22.4M | Buy |
3,619,258
+123,002
| +4% | +$760K | 0.67% | 49 |
|
|
2024
Q1 | $17.8M | Buy |
3,496,256
+225,875
| +7% | +$1.15M | 0.45% | 62 |
|
|
2023
Q4 | $19.6M | Buy |
3,270,381
+719,155
| +28% | +$4.31M | 0.48% | 60 |
|
|
2023
Q3 | $18.1M | Buy |
2,551,226
+54,033
| +2% | +$383K | 0.48% | 61 |
|
|
2023
Q2 | $17.6M | Buy |
2,497,193
+163,108
| +7% | +$1.15M | 0.42% | 61 |
|
|
2023
Q1 | $19.5M | Buy |
2,334,085
+443,348
| +23% | +$3.7M | 0.46% | 56 |
|
|
2022
Q4 | $21.7M | Buy |
1,890,737
+178,230
| +10% | +$2.05M | 0.52% | 54 |
|
|
2022
Q3 | $21.6M | Buy |
1,712,507
+251,416
| +17% | +$3.17M | 0.56% | 52 |
|
|
2022
Q2 | $15.5M | Buy |
+1,461,091
| New | +$15.5M | 0.45% | 60 |
|
|
2019
Q2 | – | Sell |
-700,000
| Closed | -$5.7M | – | 135 |
|
|
2019
Q1 | $5.7M | Hold |
700,000
| – | – | 0.22% | 104 |
|
|
2018
Q4 | $5.65M | Hold |
700,000
| – | – | 0.27% | 94 |
|
|
2018
Q3 | $5.34M | Buy |
700,000
+450,000
| +180% | +$3.43M | 0.19% | 116 |
|
|
2018
Q2 | $1.43M | Sell |
250,000
-675,000
| -73% | -$3.87M | 0.06% | 139 |
|
|
2018
Q1 | $4.41M | Buy |
925,000
+112,500
| +14% | +$537K | 0.19% | 123 |
|
|
2017
Q4 | $3.99M | Buy |
812,500
+362,500
| +81% | +$1.78M | 0.18% | 114 |
|
|
2017
Q3 | $2.36M | Buy |
+450,000
| New | +$2.36M | 0.11% | 128 |
|